Loading... Please wait...
Contact Us
Would you like more
information on this report
Please contact us today at +44(0)20.7665.9240
or +1 212.220.0880
or write to us.

Malignant Melanoma: KOL Insight 2016

Product Code:
596200644
Publication Date:
November 2016
Format:
PDF
Price:
£5,995

New combinations emerging as immunotherapies become the backbone therapy

Immunotherapies have become the go-to treatment for malignant melanoma, and with good reason. Not only are they proving to be the most effective single agents, they’re shaping up to be the backbone for a host of new combination therapies.

Learn what an immunotherapy-centric treatment algorithm means for patients and drug manufacturers in KOL Insight: Malignant Melanoma.

Twelve North American and European KOLs’ answer key questions about 9 marketed melanoma treatments and 5 currently in the pipeline.

You’ll find out which immunotherapies are most effective, and hear how they’re likely to be combined with existing and pipeline BRAF/MEK inhibitors, vaccines and immunostimulants, and other small-molecule therapies. You’ll also get insight into the key clinical trials that are shaping the market.

Request sample pages

Plus: Order the report and you’ll receive three quarterly FirstWord Therapy Trends Update Bulletins free!

See the Top Takeaways >

 “The response rate is something like 10 percent for the single [Yervoy], but the combo [Yervoy+Opdivo] is closer to 50 and 60 percent. Single agent PD-1s [Keytruda and Opdivo] are in the 40s”
US Key Opinion Leader

Sample of therapies covered:

  • Yervoy (ipilimumab; Bristol-Myers Squibb)
  • Keytruda (pembrolizumab; Merck & Co.)
  • Opdivo (nivolumab; Bristol-Myers Squibb)
  • Zelboraf (vemurafenib; Roche)/Cotellic (cobimetinib; Roche)
  • Mekinist (trametinib; GlaxoSmithKline)/Tafinlar (dabrafenib; GlaxoSmithKline)
  • Plus 9 moredownload the full list now >

Sample of KOLS interviewed

  • Igor Puzanov, MD, MSCI, FACP. Professor, Department of Medicine, Roswell Park Cancer Institute, Buffalo NY.
  • Jean-Jacques Grob, MD. Head of the Dermatology and Skin Cancer Department, Timone APHM Hospital and Aix-Marseille University, Marseille, France.
  • Philip A. Friedlander MD, PhD. Assistant Professor, Department of Dermatology, Mount Sinai School of Medicine, NY, USA.
  • Reinhard Dummer, MD. Professor, Vice-Chairman, Department of Dermatology University Hospital of Zürich, Switzerland.
  • Roger S. Lo, MD, PhD. Assistant Professor, Medicine and Molecular & Medical Pharmacology, Department of Medicine at UCLA, CA, USA.
  • Plus 7 more – download the full list now >
Back to the top

Top Takeaways

  • Immunotherapies are the new backbone: Not only have they emerged as the most effective monotherapies for melanoma patients, KOLs say they’ll soon be the backbone for most combinations as well. Which ones will see the most widespread uptake?
  • The battle for top immunotherapy is on: Will Merck’s Keytruda or BMS’ Opdivo become physicians’ first choice. KOLs are unsure, but point to a variety of factors that will drive each agent’s uptake and use in combination therapies.
  • Yervoy monotherapy down but not out: Even though immunotherapy combinations are fast becoming physicians’ first choice, KOLs note that Yervoy monotherapy won’t go away altogether. What kind of use will it continue to see?
  • Bye bye, BRAF/MEK monotherapy: KOLs rarely use single agents to treat BRAF patients. Which of the two major combination regimens do they favour?
  • Is there room for a new BRAF/MEK combination? A new encorafenib/binimetinib combination is on the way. How do KOLs expect it to fare against Roche’s Zelboraf /Cotellic and GSK’s Mekinist/Tafinlar?
  • Finding a future for Imlygic: Seen as a niche product by most KOLs, Amgen’s Imlygic has the most potential in combination. Which agents are the most likely partners for combination use? In which setting do KOLs still see a role for Imlygic monotherapy?
  • Little enthusiasm for other vaccines and immunostimulants: Do KOLs see potential for vaccines/immunostimulants other than Imlygic? What prospects do they see for the vaccine approach in general?
  • Triple threat: As the trend towards more combination therapies intensifies, KOLs expect a BRAF/MEK/PD-1 triplet combination to emerge. What will determine whether such a combination finds a place in the treatment algorithm?
Request sample pages

Back to the top

Money Back Guarantee

At FirstWord, we stand behind our reports. If you're not completely satisfied, we’ll refund your money. Guaranteed.

Ongoing Benefits

The world of pharma is ever changing and executives must always be up-to-date with new developments that could affect their own products, position and research. That is why FirstWord's guarantee to keep Therapy Trends clients up to date with Update Bulletins offers a real commercial advantage.

Update Bulletins include expert insight and analysis based on FirstWord analyst re-engagement with the KOLs after major events such as product approvals, key data releases and major conferences to deliver the most valuable insights with each update.

  • Your Therapy Trends Report purchase entitles you to receive three Update Bulletins, which are published approximately every three months for 12 months following the report's publication date.
  • You will receive a copy of each Update Bulletin once available, which are issued each quarter after the publication date.



customer.service@firstwordpharma.com

All Contents Copyright © 2020 Doctor's Guide Publishing Limited All Rights Reserved